Moderna (NSDQ:MRNA) is now the second company to release positive preliminary results from a Phase 3 trial of a COVID-19 vaccine candidate — and it appears to be more good news.
Last week, Pfizer (NYSE:PFE) announced that early data suggested its BNT162 mRNA-based vaccine was more than 90% effective at reducing symptomatic COVID-19 infections.
Today, Moderna has announced interim analysis data suggesting its mRNA-1273 is 94.5% effective.
The FDA required that the vaccine have an efficacy rate of at least 50%.
Get the whole story from our sister site, Drug Discovery & Development.